B-cell aplasia and hypogammaglobulinemia are anticipated issues after CD19-directed CAR T-cell therapy because of the off-tumor-on-target effect of CD19-associated CAR T cells on natural B cells. The gene discussed is CD19; the disease is neoplasm.